SHANGHAI, March 2, 2018 /PRNewswire/ -- CARsgen Therapeutics, a leading immune-oncology company focusing on the development of CAR-T therapies, today announces it has entered into a Pre-C financing framework agreement with receiving $60M equity investment from existing and new investors. The funds will be used in support of Investigational New Drug submissions of several CAR-T therapeutics and Next-generation CAR-T research.